Telix Pharmaceuticals Limited (TLX.XA)

18.64 +0.18 (+0.96%) At close: 03:59PM AEST

Telix Pharmaceuticals Limited

55 Flemington Road
Suite 401
North Melbourne, VIC 3051
Australia
61 3 9093 3855
https://telixpharma.com

Sector(s): 
Industry: 
Full-time employees: 415

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA	Co-Founder, MD, Group CEO & Executive Director	669.24k	N/A	1976
Mr. Darren Smith B.Bus., FCPA, M.B.A.	Group Chief Financial Officer	571.17k	N/A	1965
Dr. Andreas Kluge M.D., Ph.D.	Chief Medical Advisor & Non-Executive Director	43k	N/A	1965
Dr. David N. Cade M.B.A., M.D., MBBS	Group Chief Medical Officer	N/A	N/A	1969
Mr. Richard Valeix M.B.A.	Group Chief Commercial Officer	638.49k	N/A	1975
Mr. Darren Patti	Group Chief Operating Officer	N/A	N/A	1972
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)	Chief Scientist	141.76k	N/A	N/A
Mr. Craig Ulrick	Chief Information Officer	N/A	N/A	N/A
Ms. Kyahn Williamson B.A.	Senior Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C.	Senior VP of Global Governance, Risk & Compliance	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

Corporate governance

Telix Pharmaceuticals Limited’s ISS governance QualityScore as of 1 June 2024 is 5. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.